Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMMG-DADA: Daratumumab for first-line treatment of transplant-ineligible myeloma followed by daratumumab re-treatment at first relapse
2019-003856-35Phase 2Active
- Sponsor
- University of Cologne
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by University of Cologne. Primary endpoint: Response rate after 8 cycles of DVCd (≥VGPR). Started Aug 2020; status: active.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-003856-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003856-35.